1. Jay Wei

    0 Comments Leave a Comment

    1-15 of 57 1 2 3 4 »
    1. Mentioned In 57 Articles

    2. Optovue First in US to Receive FDA Clearance for Corneal Epithelial Thickness Mapping New Mapping Technique May be Early Indicator of Ocular Health

      Optovue First in US to Receive FDA Clearance for Corneal Epithelial Thickness Mapping New Mapping Technique May be Early Indicator of Ocular Health
      ...phy (OCT) imaging with the first non-contact technique of measuring the epithelial layer of the cornea,” said Jay Wei, founder and chief executive officer at Optovue. “Our epi-mapping software has been the subject of mor...
      Read Full Article
      Mentions: Optovue Jay Wei FDA
    3. Motion correction and normalization of features in optical coherence tomography

      Motion correction and normalization of features in optical coherence tomography
      An optical coherence tomography system is provided. The system includes an OCT imager; a two-dimensional transverse scanner coupled to the OCT imager, the two-dimensional transverse scanner receiving light from the light source and coupling reflected light from a sample into the OCT imager; a computer coupled to receive 3D OCT data from the OCT imager, the computer further processes the 3D OCT data; wherein the processing the 3D OCT data ...
      Read Full Article
      Mentions: Optovue Jay Wei
    4. Method and apparatus for enhanced eye measurements

      Method and apparatus for enhanced eye measurements
      An imaging method according to some embodiments of the present invention includes obtaining working distance information from an optical coherence tomography system, the working distance being the working distance to the sample; obtaining information from one or more ocular systems; combining the information from said optical coherence tomography information and said ocular system; and displaying said combined information.
      Read Full Article
      Mentions: Optovue Jay Wei
    5. Optovue Showcases Retinal Blood Flow Measurement Capability for Improving Management of Diabetes-Related Vision Loss

      Optovue Showcases Retinal Blood Flow Measurement Capability for Improving Management of Diabetes-Related Vision Loss
      ...low for earlier and more individualized treatment, without the need or cost of repeated dye injections,” said Jay Wei, founder and chief executive officer for Optovue. “We are very pleased with the adoption and utilizati...
      Read Full Article
    6. Enhanced biometry using optical coherence tomography

      Enhanced biometry using optical coherence tomography
      An imaging method is disclosed. An imaging method according to some embodiments can include obtaining a plurality of measurements of an eye for at least one location by scanning optical radiation across the eye; determining a preferred measurement axis from the plurality of measurements; and processing the plurality of measurements to obtain information of the eye.
      Read Full Article
    7. Scanning and processing using optical coherence tomography

      Scanning and processing using optical coherence tomography
      In accordance with some embodiments, a method of eye examination includes acquiring OCT data with a scan pattern centered on an eye cornea that includes n radial scans repeated r times, c circular scans repeated r times, and n* raster scans where the scan pattern is repeated m times, where each scan includes a A-scans, and where n is an integer that is 0 or greater, r is an integer ...
      Read Full Article
    8. Enhanced Biometry Using Optical Coherence Tomography

      Enhanced Biometry Using Optical Coherence Tomography
      An imaging method is disclosed. An imaging method according to some embodiments can include obtaining a plurality of measurements of an eye for at least one location by scanning optical radiation across the eye; determining a preferred measurement axis from the plurality of measurements; and processing the plurality of measurements to obtain information of the eye.
      Read Full Article
    9. 1-15 of 57 1 2 3 4 »
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. About Jay Wei

    Jay Wei is Founder, President, and CEO of Optovue. Jay Wei has over 14 years product development and management experience in medical device industry. He pioneered the commercialization of the optical coherence technology for ophthalmic diagnosis since 1994. Jay founded Optovue in 2004 to develop next generation Ophthalmic OCT instruments. His vision in the clinical use of OCT technology has resulted in the first FDA approved Fourier-domain OCT system, RTVue. His current role is a president/CEO of Optovue. Prior founding the Optovue, Jay was a director of advanced development and an OCT program manager at Carl Zeiss Meditec (Humphrey Instruments). He led the OCT development from ground zero in 1993 and delivered all generations of OCT products to the market. Jay has been granted over 30 patents in ophthalmic devices.

  3. Quotes

    1. Optovue continues to lead innovation in Optical Coherence Tomography (OCT) imaging with the first non-contact technique of measuring the epithelial layer of the cornea...Our epi-mapping software has been the subject of more than 200 publications, underscoring its importance and value in the care of patients with corneal and ocular surface conditions. With epi-mapping, physicians are able to quantify epithelial thickness in patients in a manner that is suitable for daily clinical practice.
      In Optovue First in US to Receive FDA Clearance for Corneal Epithelial Thickness Mapping New Mapping Technique May be Early Indicator of Ocular Health
    2. We are excited to bring to market groundbreaking technologies that provide valuable new, detailed information about the microvasculature of the eye, in a manner that reduces the burden for both the patient and the clinic staff...DualTrac Motion Correction allows for improved imaging and quicker data collection to further the clinical utility of OCTA technology by accommodating natural eye movement.
      In Optovue Announces DualTrac Motion Correction Technology for Faster, Improved Imaging
    3. We are thrilled to announce FDA clearance of our AngioVue System, which will bring the significant benefits of our innovative, non-invasive retinal imaging to patients in the U.S. who suffer from retinal diseases that lead to progressive blindness...Since we first introduced this technology to markets outside the U.S. fourteen months ago, the technology is in daily clinical use at over 525 clinical sites where it provides a more patient-friendly approach to diseases of the retina that lead to progressive blindness.
      In Optovue’s AngioVue Imaging System Receives FDA Clearance
    4. The clinical benefit to the patient and the work flow to clinics have been a major impact to society.
      In Optical Coherence Tomography Industry Has Provided Well Over 20,000 Person-Years of Direct Employment
    5. AngioVue technology has given physicians, for the first time, the ability to visualize blood vessels in the individual layers of the retina, without injections of dye...This visualization information provides physicians with a compelling new way to manage patients affected by wet age-related macular degeneration, a leading cause of blindness. We expect similar contributions to the management of diabetic retinopathy, the leading cause of blindness in diabetic patients.
      In Optovue Announces USD30 Million Private Equity Investment Agreement with Delta to Fuel Continued Innovation
    6. Avanti not only offers the new Widefield 3D Enface OCT scanning to meet today’s clinical needs, this is also a platform for future OCT innovations that will extend the clinical utility of this technology beyond what even the inventors imagined a few short years ago.
      In Optovue Launches Next Generation Widefield Enface OCT
    7. The iCam and iFusion are the latest achievements in our drive to bring enabling technology to eye care clinicians everywhere...We are pleased that once again we have achieved another step through the delivery of iFusion.
      In iFusion receives FDA clearance and begins shipping world-wide
    8. The OCT technology provided by the RTVue and iVue combined with the functional testing from the Octopus will be the best of both worlds, offering the optimum structure-function solution.
      In Haag-Streit USA and Optovue Team Up to Introduce Octopus/Optovue Bundle
    9. This FDA clearance affirms RTVue’s position as the market leader, now with the fastest scan speed of any FDA cleared device available...We continue to leverage our experience in OCT product development and Fourier-domain technology to serve the needs of physicians and patients.
      In Optovue Announces FDA 510(k) Clearance of the RTVue XR FD-OCT
    10. As the segment of post-LASIK cataract patients grows, it is increasingly important that ophthalmologists have an accurate way to determine corneal power. This FDA clearance affirms that the RTVue is a precise and effective tool that provides value for the physician and the patient...We continue to leverage our experience in OCT product development and Fourier-domain technology to serve the needs to physicians and patients.
      In Optovue Announces FDA Approval for Corneal Power Measurements